Addendum

Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Addendum to Project A26-60

Status
Status: Commission completed
Project no.
A26-121
Last updated

Report documents

  1. Addendum

    Blinatumomab (B-ALL, high-risk first relapsed, children and adolescents >= 1 month) – Addendum to Project A26-60

    published on
    Document type
    PDF document, 326 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-121

Dossier assessment

Indication:

Paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19+ B-cell precursor acute lymphoblastic leukaemia, as part of the consolidation therapy

Result of dossier assessment:

unchanged after addendum: indication of a major added benefit

Additional information

Federal Joint Committee (GBA)

19-11-2026 A G-BA decision was published.
GBA documents on this decision

Project details

Project no.
A26-121
Commission
Commission awarded on 06.10.2026 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A26-121

Connected Projects

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form